A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients.

ABSTRACT:

Background

Gene signatures measured in a biopsy have been proposed as hypoxia biomarkers in prostate cancer. We assessed a previously developed signature, and aimed to determine its relationship to hypoxia and its heterogeneity within the dominant (index) lesion of prostate cancer.

Methods

The 32-gene signature was assessed from gene expression data of 141 biopsies from the index lesion of 94 patients treated with prostatectomy. A gene score calculated from the expression levels was applied in the analyses. Hypoxic fraction from pimonidazole immunostained whole-mount and biopsy sections was used as reference standard for hypoxia.

Results

The gene score was correlated with pimonidazole-defined hypoxic fraction in whole-mount sections, and the two parameters showed almo

SUBMITTER: Salberg UB 

PROVIDER: S-EPMC9296675 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature